Interstitial Lung Disease Etiology and Diagnosis

Connective Tissue Disease-Associated ILD

• The American College of Rheumatology reports that rheumatoid arthritis accounts for 39% of CTD-ILDs, with systemic sclerosis accounting for 31% of CTD-ILDs, and Sjögren's syndrome causing autoimmune-mediated lymphocytic infiltration with characteristic patterns including NSIP, respiratory bronchiolitis, UIP, and lymphoid interstitial pneumonia 1, 2
• The European League Against Rheumatism states that idiopathic inflammatory myopathies, including dermatomyositis, polymyositis, and antisynthetase syndrome, are associated with CTD-ILD 1
• The American College of Rheumatology recommends considering systemic lupus erythematosus and mixed connective tissue disease in the diagnosis of CTD-ILD 1, 3

Environmental and Occupational Exposures

• The American Thoracic Society suggests that a detailed exposure history is mandatory because 47% of patients presenting with apparently idiopathic ILD actually have hypersensitivity pneumonitis when thoroughly evaluated 2
• The Occupational Safety and Health Administration reports that occupational inorganic dust exposures to metal, silica, and asbestos increase IPF risk with pooled odds ratio of 1.7 (95% CI 1.42-2.03) 2
• The American Lung Association states that environmental tobacco smoke increases risk and causes respiratory bronchiolitis-ILD and desquamative interstitial pneumonia 3
• The National Institute for Occupational Safety and Health recommends considering hypersensitivity pneumonitis from immune reactions to inhaled organic antigens, characterized by centrilobular nodules, mosaic air-trapping, upper lobe distribution on HRCT, and poorly formed granulomas with bronchiolocentric distribution on biopsy 3

Drug-Induced ILD

• The European Respiratory Society reports that immunosuppressive agents, including methotrexate, TNF-alpha inhibitors, cyclophosphamide, rituximab, leflunomide, sulfasalazine, and sulfonamides, carry approximately 1% risk of drug-induced ILD 4
• The American College of Chest Physicians states that nitrofurantoin toxicity can cause unclassifiable interstitial fibrosis patterns 5
• The European Respiratory Society recommends considering drug-induced ILD in CTD patients who progress despite appropriate therapy, as the medications treating the underlying disease can themselves cause ILD 4

Idiopathic Interstitial Pneumonias

• The American Thoracic Society reports that idiopathic pulmonary fibrosis (IPF) with usual interstitial pneumonia pattern represents one-third of all ILD cases 6, 3
• The European Respiratory Society states that nonspecific interstitial pneumonia (NSIP) has a differential diagnosis including autoimmune disease, hypersensitivity pneumonitis, and drug reactions 6
• The American College of Chest Physicians recommends considering cryptogenic organizing pneumonia, desquamative interstitial pneumonia, and respiratory bronchiolitis-ILD in the diagnosis of idiopathic interstitial pneumonias 6, 3

Familial/Genetic Causes

• The American Thoracic Society reports that familial interstitial pneumonia occurs in 2-20% of cases with heterozygous mutations in SFTPC, SFTPA2, TERT, and TERC accounting for 20% of familial cases 3
• The European Respiratory Society states that the MUC5B promoter variant is associated with both familial and sporadic IPF 3

Critical Diagnostic Pitfalls to Avoid

• The American College of Chest Physicians recommends obtaining sufficiently detailed exposure history to avoid missing hypersensitivity pneumonitis and other environmental exposures 2
• The European Respiratory Society states that relying solely on patient recall without standardized questionnaires misses occupational and environmental exposures 2
• The American Thoracic Society recommends considering drug-induced ILD in CTD patients who progress despite therapy, as the immunosuppressive medications themselves may be causative 4
• The American College of Medical Genetics recommends questioning family history to identify genetic predisposition that may guide management of other family members 3
• The European Respiratory Society suggests accepting "idiopathic" diagnosis without systematic exclusion of medication history, environmental exposures, connective tissue disease, and occupational exposures, because identification and removal of causative factors may result in improved clinical outcomes 2

Etiology of Interstitial Pneumonia

Environmental and Occupational Exposures

• Environmental tobacco smoke causes respiratory bronchiolitis-ILD and desquamative interstitial pneumonia, with smoking-related inclusions visible on BAL showing predominance of macrophages, according to the American Thoracic Society 7
• Quantify smoking history in pack-years to identify smoking-related ILD, as recommended by the American College of Chest Physicians 7

Diagnostic Algorithm to Identify Etiology

• BAL neutrophils >3% or eosinophils >1% suggest acute lung injury, drug reaction, or eosinophilic pneumonia, as reported in the American Journal of Respiratory and Critical Care Medicine 7
• Predominance of macrophages with smoking-related inclusions is compatible with DIP, RBILD, or Langerhans cell histiocytosis, according to the American Thoracic Society 7

Histopathologic Confirmation When Needed

• Histologic patterns with overlapping features (UIP with bronchiolocentric fibrosis, NSIP with organizing pneumonia) should prompt consideration of hypersensitivity pneumonitis, CTD-ILD, or additional injury patterns, as noted in the European Respiratory Review 8

Drug-Induced ILD

• Nitrofurantoin toxicity causes unclassifiable interstitial fibrosis patterns with patchy fibrosis, subpleural and bronchiolocentric accentuation, and prominent lymphoid aggregates, as reported in the European Respiratory Review 8

Interstitial Lung Disease in Systemic Sclerosis and Related Connective‑Tissue Diseases

Epidemiology

• Approximately half of patients with systemic sclerosis develop interstitial lung disease, which represents about one‑third of all connective‑tissue‑disease‑associated ILD cases. 9
• Sjögren syndrome is associated with interstitial lung disease in roughly 9 %–30 % of patients. [10] [11]
• Systemic lupus erythematosus shows a low prevalence of ILD, affecting only about 2 %–10 % of patients. 9

Clinical Impact

• Interstitial lung disease in systemic sclerosis carries high morbidity and contributes to early mortality in this population. 9
• Lung‑function loss in systemic‑sclerosis‑related ILD can be irreversible and may be clinically silent in early stages. 9
• The disease course is heterogeneous, ranging from subclinical imaging abnormalities to overt respiratory failure. 9
• ILD may appear before the onset of rheumatic manifestations or develop after they are established. 9
• In Sjögren syndrome, ILD confers a four‑fold increase in 10‑year mortality risk, with a 5‑year survival of approximately 85 %. [11] [12]

Histopathologic Patterns

• Nonspecific interstitial pneumonia (NSIP) is the predominant radiologic‑pathologic pattern in systemic sclerosis, polymyositis/dermatomyositis, mixed connective‑tissue disease, and Sjögren syndrome. 11

Screening Recommendations

• Systemic sclerosis – Perform baseline high‑resolution computed tomography (HRCT) and pulmonary function tests (spirometry + DLCO) at diagnosis; repeat pulmonary function tests every 6 months and HRCT annually for the first 3–4 years. 9
• Mixed connective‑tissue disease with a systemic‑sclerosis phenotype – Apply the same screening intervals as for systemic sclerosis. [10] [11] 12
• Sjögren syndrome with risk factors – Conduct annual pulmonary function tests and chest radiography; obtain HRCT if functional or radiographic abnormalities are detected. [10] [11] 12

Common Pitfalls

• Failure to screen asymptomatic systemic‑sclerosis patients allows silent progression of irreversible fibrosis. 9
• Reliance on chest radiography alone misses early or mild disease; HRCT is required for accurate assessment. [10] [11]